Viveve Medical (Viveve Medical) Cash And Cash Equivalents : $5.91 Mil (As of Sep. 2022)

View and export this data going back to 2016. Start your Free Trial

What is Viveve Medical Cash And Cash Equivalents?

Viveve Medical's quarterly cash and cash equivalents declined from Mar. 2022 ($14.05 Mil) to Jun. 2022 ($9.43 Mil) but then stayed the same from Jun. 2022 ($9.43 Mil) to Sep. 2022 ($5.91 Mil).

Viveve Medical's annual cash and cash equivalents declined from Dec. 2019 ($13.31 Mil) to Dec. 2020 ($6.52 Mil) but then increased from Dec. 2020 ($6.52 Mil) to Dec. 2021 ($19.16 Mil).

Viveve Medical Cash And Cash Equivalents Historical Data

The historical data trend for Viveve Medical's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viveve Medical Cash And Cash Equivalents Chart

Viveve Medical Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Cash And Cash Equivalents

Get a 7-Day Free Trial

20.73

29.52

13.31

6.52

19.16

Viveve Medical Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Cash And Cash Equivalents	Get a 7-Day Free Trial															22.67	19.16	14.05	9.43	5.91

Viveve Medical Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Viveve Medical (OTCPK:VIVE) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Viveve Medical Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Viveve Medical's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Viveve Medical (Viveve Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Viveve Medical Inc (OTCPK:VIVE) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

345 Inverness Drive South, Building B, Suite 250, Englewood, CO, USA, 80112

Website

https://www.viveve.com

Viveve Medical Inc designs, develops, manufactures and markets a platform medical technology. Its Cryogen-cooled Monopolar Radiofrequency technology is delivered through a radiofrequency generator, handpiece and treatment tip, called the Viveve System. The Viveve System is for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The Viveve System is indicated for use and being marketed for use in general surgical procedures for electrocoagulation and hemostasis in the United States. It has a business presence in the US, Asia Pacific, Canada, Europe and Middle East and Latin America.

Executives

Presnell Sharon Collins	director	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Goldman Sachs Group Inc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Wilmot B. Harkey	10 percent owner	C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Daniel Mack	10 percent owner	C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Nantahala Capital Management, Llc	10 percent owner	130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Karen L. Zaderej	director	AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Steven L Basta	director	1875 S GRANT STREET SUITE 110, SAN MATEO CA 94402
Scott Durbin	officer: Chief Financial Officer	PO BOX 376, ANN ARBOR MI 48106
James G. Atkinson	officer: CBO & President	150 COMMERCIAL STREET, SUNNYVALE CA 94086
Patricia Scheller	director, officer: CEO and Director	150 COMMERCIAL STREET, SUNNYVALE CA 94086
Jon M Plexico	director, 10 percent owner	16430 N SCOTTSDALE RD 450, SCOTTSDALE AZ 85254
Stonepine Capital Management, Llc	director, 10 percent owner	919 NW BOND STREET, SUITE 204, BEND OR 97703
Timothy P Lynch	director, 10 percent owner	919 NW BOND STREET, SUITE 204, BEND OR 97703
Daniel Janney	director, 10 percent owner	PO BOX 7414, JACKSON WY 83002